Unlearn.AI Closes $12M Series A to Advance the Use of Digital Twins in Clinical Trials
Summary
SAN FRANCISCO--(BUSINESS WIRE)--Unlearn.AI, developer of the first machine-learning platform that creates Digital Twins used to populate Intelligent Control Arms in clinical studies, today announced that it has closed a $12 million Series A financing. “This new financing marks an important milestone in our growth and will contribute to the significant progress we are making with regulators and with our commercial partners, who are already running studies with Digital Twins and demonstrating their value in generating robust evidence and increasing the potential for trial success,” said Charles K. Fisher, Ph.D., founder and CEO of Unlearn.AI. “As investors at the intersection of healthcare and technology, were passionate about companies that pair cutting-edge computational techniques and innovative business models to meaningfully improve patient care. To improve success rates, we need a new paradigm in trial design,” said Craig Lipset, founder of Clinical Innovation Partners and Unlearn Advisory Board member. Unlearn is working closely with biopharmaceutical and medical device companies as well as regulators to ensure its methods meet the highest scientific and regulatory standards.